Skip to main content
. 2019 Apr 11;13(3):260–269. doi: 10.1007/s12072-019-09943-6

Fig. 2.

Fig. 2

Proportion of patients with HBV DNA < 400 copies/mL over 240 weeks of treatments (ITT). a HBeAg-positive, b HBeAg-negative. ADV, adefovir dipivoxil; HBV, hepatitis B virus; ITT, intent-to-treat; TDF, tenofovir disoproxil fumarate. Data on file of global phase III pivotal studies [2, 5]